{"id":687563,"date":"2022-09-21T09:42:28","date_gmt":"2022-09-21T13:42:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/"},"modified":"2022-09-21T09:42:28","modified_gmt":"2022-09-21T13:42:28","slug":"praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/","title":{"rendered":"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference"},"content":{"rendered":"
\n

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines<\/a>, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET.<\/p>\n

The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company\u2019s website at www.praxismedicines.com<\/a>. A replay of the webcast will be available on Praxis\u2019 website for 30 days following the event.<\/p>\n

\n About Praxis<\/strong>
\n
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit\u00a0www.praxismedicines.com<\/a> and follow us on\u00a0LinkedIn<\/a>\u00a0and\u00a0Twitter<\/a>.<\/p>\n


\n
\n \n <\/div>\n

\n
Investor Contact:\r\nAlex Kane\r\nPraxis Precision Medicines\r\ninvestors@praxismedicines.com\r\n617-300-8481\r\n\r\nMedia Contact:\r\nIan Stone\r\nCanale Communications\r\nIan.stone@canalecomm.com\r\n619-849-5388<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET. The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company\u2019s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis\u2019 website for 30 days following the event. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development … <\/p>\n
Continue reading “Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687563","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPraxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET. The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company\u2019s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis\u2019 website for 30 days following the event. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development … Continue reading "Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T13:42:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference\",\"datePublished\":\"2022-09-21T13:42:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\"},\"wordCount\":203,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\",\"name\":\"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=\",\"datePublished\":\"2022-09-21T13:42:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/","og_locale":"en_US","og_type":"article","og_title":"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk","og_description":"BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Wednesday, September 28, 2022 at 11:45 a.m. ET. The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company\u2019s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis\u2019 website for 30 days following the event. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development … Continue reading \"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-21T13:42:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference","datePublished":"2022-09-21T13:42:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/"},"wordCount":203,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/","name":"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=","datePublished":"2022-09-21T13:42:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDI1MCM1MTYzMjIxIzIyMDA4OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/praxis-precision-medicines-to-present-at-guggenheim-nantucket-therapeutics-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687563"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687563\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}